EUROSCAN INTERNATIONAL NETWORK EV

Their core work

EuroScan International Network is a collaborative network of health technology assessment (HTA) agencies and research bodies that specializes in horizon scanning — identifying, tracking, and evaluating emerging health technologies before they reach widespread clinical adoption. Based in Köln, Germany, the network brings together member organizations from across Europe and beyond to share structured intelligence on new medical devices, diagnostics, and treatments. In H2020, EuroScan contributed HTA methodology and safety evaluation expertise to projects covering nanotechnology-based medical devices and patient-centric adaptive clinical trial platforms. Their value to consortia lies in their cross-national network reach and systematic approach to early technology evaluation.

What they specialise in

How they've shifted over time

Both H2020 projects began in 2019, but their keyword profiles reveal a meaningful thematic range within EuroScan's portfolio. Their earlier project engagement centered on the physical safety and regulatory lifecycle of nanotechnology-based medical devices and in vitro diagnostics. Their second project shifted toward clinical research infrastructure — Bayesian adaptive trials, data governance, patient-centredness, and specific disease contexts including major depressive disorder, tuberculosis, and neurofibromatosis. The trajectory suggests EuroScan is expanding from upstream technology scanning toward active involvement in clinical trial design and real-world evidence generation, tracking the direction HTA methodology is heading across Europe.

EuroScan appears to be moving from upstream technology scanning toward active involvement in clinical research platforms, making them a relevant partner for projects bridging HTA with real-world evidence generation and regulatory approval pathways.

How they like to work

EuroScan participates exclusively as a consortium partner, never as project coordinator — consistent with a network body that contributes methodological expertise and cross-national reach rather than direct project leadership. Despite only two projects, they engaged with 74 distinct partners across 24 countries, indicating they join large, multi-stakeholder consortia where their HTA network membership adds structural legitimacy. This profile suggests a reliable specialist contributor who brings credibility and geographic breadth rather than hands-on project management capacity.

EuroScan has engaged with 74 unique consortium partners across 24 countries from just two projects — an unusually broad reach that reflects the multi-national membership structure of the network itself rather than bilateral research ties. Their European base in Germany anchors operations, but partnerships span the full EU research geography.

What sets them apart

EuroScan's core differentiator is its organizational form: it is a network of HTA bodies rather than a single research institution, which means a project partner gains access to evaluation capacity spread across multiple countries simultaneously. This is particularly valuable for multi-country health technology assessments, where national regulatory context shapes adoption pathways. Very few organizations in H2020 can offer both the methodological depth of HTA and the multi-national intelligence infrastructure that EuroScan's network model provides.

Highlights from their portfolio

• SAFE-N-MEDTECH
  EuroScan's largest H2020 grant (€346,250) placed the network at the frontier of nanomaterial safety assessment for regulated medical products — a technically demanding domain combining materials science, toxicology, and EU regulatory frameworks for devices and IVDs.
• EU-PEARL
  EU-PEARL tackled one of the hardest problems in clinical research — designing patient-centric platform trials across multiple disease areas simultaneously using Bayesian statistics — giving EuroScan direct involvement in next-generation trial design and data governance infrastructure.